Want to see HK:2453 full AI Analyst Report?
Top Page
Concord Healthcare Group Co., Ltd. Class H
(2453)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.75
▼(-59.18% Downside)
Action:Reiterated
Date:07/15/26
The score is primarily weighed down by weak financial performance: large operating and net losses, negative operating/free cash flow in 2024–2025, and elevated leverage. Technicals also detract, with the stock trading below all major moving averages and negative MACD signaling a sustained downtrend. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Revenue Recovery
The 2025 revenue rebound shows that demand for the company’s oncology-related services and products can recover after volatility. If sustained, stronger top-line activity could improve operating leverage, support investment in hospital projects, and provide a foundation for future earnings improvement.
Negative Factors
Persistent Operating Losses
Deep operating and net losses show that the recent revenue recovery has not yet translated into a viable earnings model. Continued losses can restrict reinvestment, weaken returns on shareholder capital, and require management to improve pricing, utilization, and cost control before profitability becomes durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The 2025 revenue rebound shows that demand for the company’s oncology-related services and products can recover after volatility. If sustained, stronger top-line activity could improve operating leverage, support investment in hospital projects, and provide a foundation for future earnings improvement.
Read all positive factors
Concord Healthcare Group Co., Ltd. Class H (2453) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$579.91M
Dividend YieldN/A
Average Volume (3M)263.84K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue Growth47.93%
EPS Growth65.94%
CountryHK
Employees592
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.20
Shares Outstanding313,874,630
10 Day Avg. Volume151,200
30 Day Avg. Volume263,840
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.62
Price to Sales (P/S)2.55
P/FCF Ratio-4.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Concord Healthcare Group Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation o...
How the Company Makes Money
Concord Healthcare Group primarily generates revenue through a combination of service fees and product-related income tied to oncology and hospital-based clinical infrastructure. A key revenue stream is the provision of management and operational ...
Concord Healthcare Group Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 513.04M | 448.02M | 388.31M | 538.65M | 472.17M | 470.50M |
| Gross Profit | 102.69M | 31.12M | -67.25M | -65.09M | -197.46M | -92.76M |
| EBITDA | 29.33M | -64.03M | -194.46M | -172.58M | -355.51M | -356.26M |
| Net Income | -154.94M | -249.96M | -443.22M | -373.09M | -541.40M | -816.59M |
Balance Sheet | ||||||
| Total Assets | 5.66B | 5.79B | 5.91B | 5.24B | 6.08B | 6.66B |
| Cash, Cash Equivalents and Short-Term Investments | 161.74M | 319.01M | 337.12M | 49.23M | 136.06M | 136.09M |
| Total Debt | 3.06B | 3.09B | 3.21B | 2.64B | 2.85B | 2.48B |
| Total Liabilities | 3.73B | 3.76B | 4.01B | 3.37B | 3.84B | 8.08B |
| Stockholders Equity | 1.75B | 1.83B | 1.65B | 1.60B | 1.69B | -1.56B |
Cash Flow | ||||||
| Free Cash Flow | -113.76M | -259.95M | -500.12M | 18.11M | -175.66M | -584.24M |
| Operating Cash Flow | -117.54M | -113.08M | -185.96M | 201.85M | -93.64M | 45.87M |
| Investing Cash Flow | 52.44M | 110.91M | -668.09M | -182.34M | -100.33M | -945.04M |
| Financing Cash Flow | 8.15M | 92.10M | 1.02B | -105.43M | 184.37M | 505.06M |
Concord Healthcare Group Co., Ltd. Class H Technical Analysis
Negative
1.83
Price Trends
0.77
Negative
0.97
Negative
1.30
Negative
Market Momentum
>-0.01
Positive
41.21
Neutral
15.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2453, the sentiment is Negative. The current price of 1.83 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.77, and above the 200-day MA of 1.30, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.21 is Neutral, neither overbought nor oversold. The STOCH value of 15.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2453.
Concord Healthcare Group Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$1.05B | 9.86 | 5.57% | 2.35% | 4.75% | ― | |
62 Neutral | HK$469.86M | -145.42 | -0.41% | ― | 3.16% | -101.02% | |
62 Neutral | HK$6.41B | 30.32 | 2.50% | 0.39% | 1.59% | -58.55% | |
56 Neutral | HK$1.18B | 86.19 | 0.48% | 0.99% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.03B | 31.31 | 1.27% | ― | ― | ― | |
44 Neutral | HK$579.91M | -3.25 | -8.65% | ― | 47.93% | 65.94% |
* Healthcare Sector Average
HK:2453
Concord Healthcare Group Co., Ltd. Class H
0.75
-2.57
-77.41%
HK:3309
C-MER Eye Care Holdings Limited
0.83
-1.05
-55.87%
HK:3869
Hospital Corporation of China Ltd
3.40
-3.39
-49.93%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-30.92%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
10.28
-4.05
-28.26%
HK:6639
Arrail Group Ltd.
1.83
-0.44
-19.43%
Concord Healthcare Group Co., Ltd. Class H Corporate Events
Concord Healthcare’s Controlling Shareholder Renews Share Pledge for Smaller Loan Facility
Sep 1, 2026
Concord Healthcare Group Co., Ltd. has disclosed that its controlling shareholder, Shanghai Medstar, has fully released a previous pledge over domestic shares linked to a RMB500 million loan facility. On the same day, Shanghai Medstar entered into...
Concord Healthcare Narrows Loss as Hospital Revenue Surges in First Half 2026
Aug 21, 2026
Concord Healthcare Group reported a sharp improvement in operating performance for the six months ended June 30, 2026, driven by strong growth in its core hospital operations. Revenue rose 34.2% year-on-year to RMB269.6 million, with hospital oper...
Concord Healthcare Schedules Board Meeting to Review Interim Results and Dividend
Aug 11, 2026
Concord Healthcare Group Co., Ltd., a PRC-based healthcare group listed in Hong Kong, operates through multiple subsidiaries to deliver medical and healthcare services, with governance overseen by a board comprising executive, non-executive, indep...
Concord Healthcare Flags Surging First-Half 2026 Profit on Proton Therapy Growth
Jul 30, 2026
Concord Healthcare Group has issued a profit alert indicating a sharp improvement in its financial performance for the six months ended June 30, 2026, based on preliminary unaudited figures. The group expects revenue of about RMB260 million to RMB...
Concord Healthcare Seals Uzbekistan PPP for Gamma Knife Cancer Centre
Jul 29, 2026
Concord Healthcare Group has signed a public-private partnership agreement with Uzbekistan’s Ministry of Health to fully invest in and operate a Gamma Knife stereotactic radiosurgery centre at the Tashkent National Medical Centre for a 15-ye...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.